Therapeutic Areas | Swixx BioPharma | Modern Medicines for All

There are more than 7,000 known rare diseases. Most of them are chronic, debilitating, or even life-threatening, and more than half affect children. They are characterized by a broad diversity of disorders and symptoms that vary not only from disease to disease but also from patient to patient. Rare diseases affect approximately 300 million patients worldwide. Due to unspecific symptoms and suboptimal awareness, the journey to the right diagnosis takes on average 6 to 8 years and usually several misdiagnoses along the way. Shortening this diagnostic journey can improve quality of life, help patients and families to understand their disease, and avoid unnecessary interventions. Earlier diagnosis is also crucial in providing more time for efficacious therapeutic interventions before irreversible damage.

The Rare disease therapeutic area is a heritage focus of Swixx BioPharma. At Swixx we are proud to emphasize that our company enables the treatment of the largest number of rare diseases in comparison to our competitors - almost twenty. Swixx experts have extensive knowledge and a long-term history of achieving successful results in enabling patient’s access to modern medicines of our partners, helping them live better lives.

Swixx partners with the following innovative companies in this therapeutic area: AstraZeneca/Alexion, BioCryst, Jazz Pharmaceuticals, Kyowa Kirin, Otsuka, PTC and Sanofi.

The most common cancers are breast, lung, colon, rectum and prostate, and many can be cured if detected early and treated effectively. Although the progress in the early detection and treatment of cancer in recent decades has led to a dramatic increase in the number of cancer survivors, metastatic complications and comorbidities are still a significant medical challenge. Continuous medical education, a multidisciplinary approach and access to high-quality treatments are critical to improved patient outcomes.

At Swixx we stand in solidarity with cancer patients. We are committed to unlock access to modern medicines of our partners, so that CEE cancer patients can enjoy the same life expectancy and quality of life as patients in Western Europe.

Swixx BioPharma provides cutting-edge treatments in breast, renal, non-small cell lung, head and neck cancers, melanoma, and many hematologic cancers through our numerous partnerships with innovative biotech companies such as Amgen, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Gilead, Incyte, Jazz Pharmaceuticals, Kyowa Kirin, Sanofi, Seagen, and YmABs.

Swixx experts in our Specialty care Business Unit are dedicated to bringing modern, cost-effective medicines closer to patients living with chronic diseases in the therapeutic areas of Cardiovascular diseases, Diabetes, Multiple Sclerosis, Iron Deficiency / Anemia, Gastroenterology, Gynecology & Obstetrics and CNS (Epilepsy and Psychiatry). Our growing portfolio of medicines in chronic diseases therapeutic areas is supported by strong medical and commercial teams. We employ modern approaches in the education of healthcare professionals through webinars, regional activities and omnichannel marketing. Our partnerships by therapeutic areas include: ALK (immunotherapy of allergies), Indivior (substance-use disorders and serious mental illnesses), Gilead (HIV, invasive mycosis and HCV), Norgine (labor induction and bowel cleansers), Otsuka (schizophrenia), Sanofi (cardiovascular disease, diabetes, epilepsy and multiple sclerosis), Vifor (iron deficiency/anemia).

Vaccination represents the most effective public health intervention in the world for saving lives and promoting good health. Each year up to 5 million lives are saved worldwide thanks to vaccination. The vaccination coverage rate presents a vital indicator for protecting the public from highly contagious diseases.

Due to vaccination, diseases such as diphtheria and poliomyelitis have almost been eradicated and many lethal infectious diseases are avoided. Certain life-threatening conditions can also be prevented with vaccination. It is proven that Flu makes you 6 times more likely to have a heart attack in the 7 days following infection.

Because it is estimated that 1.5 million deaths could be avoided with improved vaccination coverage, the main priority of Swixx local organizations is to ensure the availability of vaccines in the Central Eastern European and CIS region. Our mission is to help protect the people at every stage of life while assuring the implementation of various national immunization programs.

To meet our mission, Swixx experts in individual countries are collaborating with leading national and international scientific experts, support the education of HCPs, and engage in activities to raise public awareness about the benefits of vaccination for patients and societies as a whole.

Swixx represents the full portfolio of Sanofi, from Flu and Travel vaccines to Primary vaccination and boosters across 15 countries. We plan to expand our vaccines coverage to Czech Republic, Hungary, Poland and Romania in the future.